Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Onto Innovation (ONTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Onto Innovation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Onto Innovation trades at $235 (market cap $12.93B). The key difference: Onto Innovation is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Onto Innovation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Onto Innovation for 7 Days on average.
| KYMR | ONTO | |
|---|---|---|
Market Cap | $8.87B | $12.93B |
Volume | 779,107 | 1,098,259 |
Sector | Health | Technology |
52-Week High | $127.31 | $378.45 |
52-Week Low | $55.80 | $124.09 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $8.26B | $12.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ONTO trades at $263.55, down 3.72% with bearish technical signals but strong analyst support. The stock shows mixed earnings performance with a Q2 2026 beat but misses in prior quarters. Revenue grew to $1.01B in 2025 with 11.84% net margin, though valuation remains elevated at P/E 98.71. Recent news highlights a $1.1B backlog and strategic partnerships in semiconductor manufacturing.
Outlook remains positive with 100% analyst buy ratings and $387 consensus target suggesting 47% upside. Key risks include high valuation multiples and semiconductor cycle volatility. Growth catalysts include AI-driven demand and Dragonfly G5 product momentum, though execution on backlog conversion is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →
